Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022
January 10 2023 - 4:05PM
Iridex Corporation (Nasdaq: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, today provided preliminary unaudited
operational and financial results for the fourth quarter and full
year ended December 31, 2022.
Fourth Quarter 2022 Results
- Total revenue is expected to be between $15.1 million and $15.3
million, unchanged compared to last year’s fourth quarter
- Sold a new record 16,400 Cyclo G6® probes, representing fourth
quarter growth of 8% compared to the prior year quarter
- Sold 78 Cyclo G6® Glaucoma Laser Systems in the fourth quarter
of 2022, compared to 90 in the prior year quarter
- Cash and cash equivalents totaled approximately $13.9 million
as of December 31, 2022, reflecting operating cash usage of
approximately $1.2 million in the fourth quarter, and approximately
$6.0 million for the full year 2022. During 2022, the company added
$4.0 million to inventory and prepaid materials to mitigate supply
chain constraints, which are expected to unwind throughout
2023.
Full Year 2022 Results
- Total revenue is expected to be between $56.9 million and $57.1
million, with the midpoint representing growth of 6% compared to
$53.9 million in 2021
- Sold 59,800 Cyclo G6® probes, compared to 58,200 in the prior
year
- Sold 237 Cyclo G6® Glaucoma Laser Systems compared to 243 in
the prior year
“We are pleased with our improved results in the second half of
the year driven by record fourth quarter Cyclo G6 probe sales, the
expanding base of Cyclo G6 Glaucoma Laser Systems and strong
performance in the retina laser business,” said David I.
Bruce, President and CEO of Iridex. “We are focused on driving
growth in 2023 as we execute our initiatives to increase Cyclo G6
utilization and adoption globally and execute the worldwide rollout
of our new platforms for Pascal® scanning laser and IQ line of
retina lasers.”
These preliminary results are based on management's initial
analysis of operations for the quarter and year ended December
31, 2022 and are subject to completion of the Company’s
year-end financial reporting processes, further internal review,
potential adjustments and audit by the Company's external
auditors.
About IridexIridex Corporation is a
worldwide leader in developing, manufacturing, and marketing
innovative and versatile laser-based medical systems, delivery
devices and consumable instrumentation for the ophthalmology
market. The Company’s proprietary MicroPulse® technology delivers a
differentiated treatment that provides safe, effective, and proven
treatment for targeted sight-threatening eye conditions. Iridex’s
current product line is used for the treatment of glaucoma and
diabetic macular edema (DME) and other retinal diseases. Iridex
products are sold in the United States through a direct sales force
and internationally primarily through a network of independent
distributors into more than 100 countries. For further information,
visit the Iridex website at www.iridex.com.
Safe Harbor StatementThis announcement contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Act of 1934, as amended, including those statements
concerning clinical and commercial momentum, market adoption and
expansion, demand for and utilization of the Company's products,
financial results and sales volumes. These statements are not
guarantees of future performance and actual results may differ
materially from those described in these forward-looking statements
as a result of a number of factors. Please see a detailed
description of these and other risks contained in our Quarterly
Report on Form 10-Q for the third quarter, filed with the
Securities and Exchange Commission on November 10, 2022.
Forward-looking statements contained in this announcement are made
as of this date and will not be updated.
Investor Relations ContactPhilip
Taylorinvestors@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Aug 2023 to Aug 2024